LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noad078 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Emily C Hardin und 36 weiteren Autor:innen. Beteiligte Einrichtung: Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Glioma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Brain Tumour Charity, Pediatric Brain Tumor Foundation, Deutsche Kinderkrebsstiftung.
Abstract (Originalsprache)
Background
The international, multicenter registry LOGGIC Core BioClinical Data Bank aims to enhance the understanding of tumor biology in pediatric low-grade glioma (pLGG) and provide clinical and molecular data to support treatment decisions and interventional trial participation. Hence, the question arises whether implementation of RNA sequencing (RNA-Seq) using fresh frozen (FrFr) tumor tissue in addition to gene panel and DNA methylation analysis improves diagnostic accuracy and provides additional clinical benefit.
Methods
Analysis of patients aged 0 to 21 years, enrolled in Germany between April 2019 and February 2021, and for whom FrFr tissue was available. Central reference histopathology, immunohistochemistry, 850k DNA methylation analysis, gene panel sequencing, and RNA-Seq were performed.
Results
FrFr tissue was available in 178/379 enrolled cases. RNA-Seq was performed on 125 of these samples. We confirmed KIAA1549::BRAF-fusion (n = 71), BRAF V600E-mutation (n = 12), and alterations in FGFR1 (n = 14) as the most frequent alterations, among other common molecular drivers (n = 12). N = 16 cases (13%) presented rare gene fusions (eg, TPM3::NTRK1, EWSR1::VGLL1, SH3PXD2A::HTRA1, PDGFB::LRP1, GOPC::ROS1). In n = 27 cases (22%), RNA-Seq detected a driver alteration not otherwise identified (22/27 actionable). The rate of driver alteration detection was hereby increased from 75% to 97%. Furthermore, FGFR1 internal tandem duplications (n = 6) were only detected by RNA-Seq using current bioinformatics pipelines, leading to a change in analysis protocols.
Conclusions
The addition of RNA-Seq to current diagnostic methods improves diagnostic accuracy, making precision oncology treatments (MEKi/RAFi/ERKi/NTRKi/FGFRi/ROSi) more accessible. We propose to include RNA-Seq as part of routine diagnostics for all pLGG patients, especially when no common pLGG alteration was identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
- Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- German Cancer Consortium (DKTK).
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.
- Heidelberg Medical Faculty, University of Heidelberg, Heidelberg, Germany.
- National Center for Tumor Diseases (NCT), Heidelberg, Germany.
ORCID-Profile: Till Milde, Stefan M Pfister, Päivi Lähteenmäki, David S Ziegler, Pablo Hernáiz Driever, David Capper, Felix Sahm, Cornelis M van Tilburg
Förderung
- Brain Tumour Charity
- Pediatric Brain Tumor Foundation
- Deutsche Kinderkrebsstiftung
Zitieren
APA
Hardin, E. C., Schmid, S., Sommerkamp, A., Bodden, C., Heipertz, A. E., Sievers, P., Wittmann, A., Milde, T., Pfister, S. M., von Deimling, A., Horn, S., Herz, N. A., Simon, M., Perera, A. A., Azizi, A., Cruz, O., Curry, S., Van Damme, A., Garami, M., …, & van Tilburg, C. M. (2023). LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad078
Vancouver
Hardin EC, Schmid S, Sommerkamp A, Bodden C, Heipertz AE, Sievers P, et al. LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad078
BibTeX
@article{Hardin2023,
author = {Hardin, Emily C and Schmid, Simone and Sommerkamp, Alexander and Bodden, Carina and Heipertz, Anna-Elisa and Sievers, Philipp and Wittmann, Andrea and Milde, Till and Pfister, Stefan M and von Deimling, Andreas and Horn, Svea and Herz, Nina A and Simon, Michèle and Perera, Ashwyn A and Azizi, Amedeo and Cruz, Ofelia and Curry, Sarah and Van Damme, An and Garami, Miklos and Hargrave, Darren and Kattamis, Antonis and Kotnik, Barbara Faganel and Lähteenmäki, Päivi and Scheinemann, Katrin and Schouten-van Meeteren, Antoinette Y N and Sehested, Astrid and Viscardi, Elisabetta and Wormdal, Ole Mikal and Zapotocky, Michal and Ziegler, David S and Koch, Arend and Hernáiz Driever, Pablo and Witt, Olaf and Capper, David and Sahm, Felix and Jones, David T W and van Tilburg, Cornelis M},
title = {LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noad078}
}
EUVIMED